CD274 and lung carcinoma: Moreover, the efficacy of other PD-1 or PD-L1 inhibitors, like pembrolizumab (PEARIS, NCT02504372), durvalumab (BR31, NCT02273375), and atezolizumab (IMPOWER010, NCT02486718), in treating early stage lung cancer is being evaluated in ongoing clinical trials.